For outsourcing facilities under section 503B, FDA does not intend to take action against compounders for violations of the FD&C Act arising from conditions that depend on tirzepatide injection products inclusion on FDAs drug shortage list until March 19, 2025. Semaglutide The timeframes during which the agency does not intend to take action against compounders for violations of the FD&C Act arising from conditions that depend on semaglutide injection products inclusion on FDAs drug shortage list are: For a state-licensed pharmacy or physician compounding under section 503A of the FD&C Act, until April 22, 2025, or until the date of the district courts decision on the plaintiffs forthcoming preliminary injunction motion in Outsourcing Facilities Association (OFA) v

So people had decided they had lost enough or too much and they were done. Basically, if weight loss is your main health goal, you may find retatrutide works a little too well, and a less powerful drug or lifestyle changes may be better for you
Combining different medication classes can sometimes produce additive effects, though this approach requires careful medical supervision
The Deseq2 package in R was employed for the calculation of log2 fold changes in transcript expression
doi:10.1371/journal.pone.0107129 Mikes V, Dadk V
Zakko 2018